NCT02043912

Drug Interactions With Risk of QT-prolongation in a General Hospital

Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 222 (actual)
• Sponsor: KU Leuven · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

Detailed description

Study design: epidemiological point prevalence study Target population: Patients with haloperidol treatment The following aspects will be investigated: * The medication profiles will be checked for drug interactions with risk of QT-prolongation. * Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected. * Safety measurements (e.g. ECG) will be documented.

Conditions

• QT-prolongation

Interventions

Type	Name	Description
DRUG	Haloperidol

Timeline

• Start date: 2013-07-01
• Primary completion: 2014-02-01
• Completion: 2014-04-01
• First posted: 2014-01-23
• Last updated: 2014-06-11

Locations

1 site across 1 country: Belgium